CATB Catabasis Pharmaceuticals, Inc.

1.52
0  -3%
Previous Close 1.57
Open 1.57
Price To book 1.02
Market Cap 28.72M
Shares 18,898,000
Volume 243,744
Short Ratio 0.43
Av. Daily Volume 1,976,420

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a did not meet primary endpoint - June 2016
CAT-2054
Hypercholesterolemia
Phase 1/2 Part B top-line data released January 31, 2017 - endpoint not met. Part C data due in 2017, with an interim update in 2Q.
CAT-1004
Duchenne muscular dystrophy (DMD)

Latest News

  1. Catabasis Pharmaceuticals to Present at the American Academy of Neurology 69th Annual Meeting
  2. Edited Transcript of CATB earnings conference call or presentation 16-Mar-17 8:30pm GMT
  3. Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Highlights
  4. Catabasis Pharmaceuticals to Present at Oppenheimer’s 27th Annual Healthcare Conference
  5. Sarepta's DMD Drug Launch Slow; What's in Store for 2017?
  6. Catabasis Pharmaceuticals to Present at the 2017 Muscular Dystrophy Association Scientific Conference
  7. Catabasis Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate Developments on Thursday, March 16
  8. Catabasis Pharmaceuticals to Present at Cowen and Company 37th Annual Health Care Conference
  9. Catabasis Pharmaceuticals Announces Promotion of Ted Hibben to Chief Business Officer
  10. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Catabasis Pharmaceuticals, Inc.
  11. Catabasis Hits 52-Week Low on Poor DMD Drug Study Data
  12. Biotech Stock Roundup: Celgene, Biogen, ABBV Post Q4 Results, Catabasis Falls on DMD Data
  13. Catabasis Drops After Muscular Dystrophy Drug Fails
  14. Catabasis Pharmaceuticals Inc (CATB): What’s Next?
  15. Catabasis Pharma stock sinks 69% after negative mid-stage clinical trial results for DMD drug
  16. Catabasis shares plummet on Duchenne trial failure
  17. Catabasis Pharmaceuticals Announces Top-Line Results for Part B of the MoveDMD® Trial for Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy
  18. Catabasis Muscular Dystrophy Drug Posts Early Win
  19. Thursday’s Top Biopharma Movers